Weight loss drugs redefine treatment but long term support is crucial

Two breakthrough drugs, Wegovy and Mounjaro, are reshaping how obesity is treated. Delivered via weekly self-injections, they mimic hormones that suppress appetite, while Mounjaro also regulates metabolism and energy balance.

Clinical trials show rapid results. Mounjaro patients lost around 20% of body weight over 72 weeks compared with 14% on Wegovy. Earlier studies showed Wegovy users could shed more than 10% in a year when combined with diet and lifestyle changes.

But research also highlights the challenge. Most people regain weight within a year of stopping treatment as food cravings return. Experts argue long-term success depends on sustained NHS support, including nutrition advice, structured exercise and community-based programmes.

Read more here to explore what this means for the future of obesity care.